Literature DB >> 17402829

Surrogate markers to assess new therapies for drug-resistant tuberculosis.

Robert S Wallis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17402829     DOI： 10.1586/14787210.5.2.163

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


× No keyword cloud information.
  3 in total

1.  Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

Authors:  Payam Nahid; Erin Bliven-Sizemore; Leah G Jarlsberg; Mary A De Groote; John L Johnson; Grace Muzanyi; Melissa Engle; Marc Weiner; Nebojsa Janjic; David G Sterling; Urs A Ochsner
Journal:  Tuberculosis (Edinb)       Date:  2014-02-07       Impact factor: 3.131

2.  An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.

Authors:  Patrick P J Phillips; Katherine Fielding; Andrew J Nunn
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

3.  Predictors of delayed culture conversion among Ugandan patients.

Authors:  Daniel Atwine; Patrick Orikiriza; Ivan Taremwa; Arnold Ayebare; Suzan Logoose; Juliet Mwanga-Amumpaire; Amina Jindani; Maryline Bonnet
Journal:  BMC Infect Dis       Date:  2017-04-24       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.